Abstract: The present disclosure provides stable liquid formulations of cyclophosphamide. The stable liquid formulations are free from co-solvents and acidifying agents. The stable liquid formulations cyclophosphamide contains cyclophosphamide monohydrate or cyclophosphamide anhydrous, ethanol, and one or more antioxidants.

Abstract: A pharmaceutically acceptable intranasal spray formulation includes about 0.01% w/v to about 5% w/v melatonin, about 0% w/v to about 50% w/v liquid solvent selected from the group consisting of alcohol, polyethylene glycol, propylene glycol and combinations thereof, a pH system in an amount effective to maintain a pH of the formulation at about 4.5 to about 6.5, at least one preservative, and water. An aqueous formulation of melatonin for nasal administration as an in-situ gel includes melatonin, water, at least one organic solvent, and at least one gelling agent.